Prescription medication · Anticonvulsant (Sulfonamide)
zonisamide
Also sold as Zonegran. Zonisamide is used to treat partial seizures in adults who have epilepsy.
Data updated 2026-05-15
- 14,210
- FDA reportsModerately reported
- 13
- InteractionsSeveral interactions
- $0.10
- Generic price (NADAC)
What the data shows
zonisamide (Zonegran) is a prescription Anticonvulsant (Sulfonamide), reported less often than most tracked drugs (14,210 FDA reports), with 13 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
zonisamide (Zonegran) is a prescription Anticonvulsant (Sulfonamide). Zonisamide is used to treat partial seizures in adults who have epilepsy.
Zonisamide is a medicine used with other medicines to treat partial seizures in adults with epilepsy. It belongs to a class of drugs called anticonvulsants.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$0.10/unit
Generic Available
Yes (6 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Zonisamide is used to treat partial seizures in adults who have epilepsy.
Common side effects
Feeling sleepy, Loss of appetite, Dizziness
Key warnings
If you are allergic to sulfonamide medicines, you should not take zonisamide.
The sections below are summarized in plain English from zonisamide's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Zonisamide works by slowing down the electrical signals in the brain that cause seizures. It is thought to stabilize nerve cell membranes, which reduces the chance of seizures. It may also affect certain chemicals in the brain.
Side Effects (from patient reports)
Based on 14,210 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for zonisamide, by number of reports
- Seizure
Seizure
1,574 reports
- Fatigue
Fatigue
697 reports
- Somnolence
Somnolence
645 reports
- Convulsion 623
Convulsion
623 reports
- Dizziness 558
Dizziness
558 reports
- Nausea 550
Nausea
550 reports
- Headache 543
Headache
543 reports
- Fall 496
Fall
496 reports
- Drug Interaction 466
Drug Interaction
466 reports
- Condition Aggravated 447
Condition Aggravated
447 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for zonisamide each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where zonisamide sits
zonisamide has more FDA adverse-event reports than 47% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is zonisamide; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 14,210 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
14,210
Reports Mentioning Death
869
6.1% of reports — not proof of cause
Hospitalization Reports
4,400
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | SEIZURE | 1,574 |
| 4 | FATIGUE | 697 |
| 5 | SOMNOLENCE | 645 |
| 6 | CONVULSION | 623 |
| 7 | DIZZINESS | 558 |
| 8 | NAUSEA | 550 |
| 9 | HEADACHE | 543 |
| 10 | FALL | 496 |
| 11 | DRUG INTERACTION | 466 |
| 12 | CONDITION AGGRAVATED | 447 |
| 13 | VOMITING | 438 |
| 14 | DIARRHOEA | 412 |
| 15 | EPILEPSY | 378 |
| 16 | WEIGHT DECREASED | 361 |
| 17 | DEPRESSION | 358 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
If you are allergic to sulfonamide medicines, you should not take zonisamide. Using zonisamide with other medicines that also inhibit carbonic anhydrase (like topiramate) can increase the risk of metabolic acidosis, kidney stones, and high ammonia levels in the blood.
Known Drug Interactions
Examples: Topiramate, zonisamide, acetazolamide or dichlorphenamide Drugs that Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Mechanism: Zonisamide interferes with how your kidneys remove metformin from your body, which can increase the risk of a serious condition called lactic acidosis.
7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin.
Mechanism: Both drugs can cause a buildup of acid in the blood. Taking them together increases the risk of a serious condition called lactic acidosis.
7.2 Other Carbonic Anhydrase Inhibitors Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide or acetazolamide) may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation.
Mechanism: Both drugs block the same enzyme, which can make your blood too acidic. This combination also makes it more likely that you will develop kidney stones.
In addition, carbamazepine causes, or would be expected to cause, decreased levels of the following drugs, for which monitoring of concentrations or dosage adjustment may be necessary: acetaminophen, albendazole, alprazolam, aprepitant, buprenorphone, bupropion, citalopram, clonazepam, clozapine, corticosteroids (e.g., prednisolone, dexamethasone), cyclosporine, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, mianserin, midazolam,...
Mechanism: Carbamazepine speeds up how quickly your body breaks down zonisamide, which can make the zonisamide less effective.
Table 4 Clinically Relevant Interactions with SYNJARDY or SYNJARDY XR Carbonic Anhydrase Inhibitors Clinical Impact Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.
Mechanism: Zonisamide can cause a buildup of acid in your blood by lowering bicarbonate levels. Taking it with this medicine may increase the risk of this chemical imbalance.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I drink alcohol while taking zonisamide?
How long does it take for zonisamide to start working?
Can I stop taking zonisamide suddenly?
Does zonisamide cause weight loss?
Can zonisamide affect my thinking?
What should I do if I experience side effects?
Can I take zonisamide with other medications?
Will zonisamide cure my epilepsy?
What size capsules does zonisamide come in?
Where can I find more information about zonisamide?
What are the common side effects of zonisamide?
Does zonisamide interact with other medications?
What drug class is zonisamide?
What pregnancy or breastfeeding source fields are listed for zonisamide?
Related Medications in Anticonvulsant (Sulfonamide)
Other drugs grouped near zonisamide - same-class peers and common alternatives.
brivaracetam
Briviact
Brivaracetam is a medicine used to treat partial-onset seizures.
Compare with zonisamide →
cannabidiol
Epidiolex
Epidiolex is a medicine that contains cannabidiol.
Compare with zonisamide →
carbamazepine
Tegretol
Carbamazepine is a medicine used to control seizures and treat nerve pain.
Compare with zonisamide →
cenobamate
Xcopri
Xcopri is a medicine used to treat partial-onset seizures in adults.
Compare with zonisamide →
clobazam
Onfi, Sympazan
Clobazam oral suspension is a medicine used with other medicines to treat seizures caused by Lennox-Gastaut syndrome.
Compare with zonisamide →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for zonisamide: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 14,210.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 6.12%.
- infliximab Δ 0.03 pts · 211,136 reports · TNF-Alpha Inhibitor (Biologic) 6.15%death share
- rosuvastatin Δ 0.10 pts · 194,743 reports · HMG-CoA Reductase Inhibitor (Statin) 6.02%death share
- baloxavir marboxil Δ 0.11 pts · 2,164 reports · Endonuclease Inhibitor (Antiviral) 6.01%death share
- terbinafine Δ 0.13 pts · 6,848 reports · Allylamine Antifungal 6.25%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on zonisamide
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for zonisamide
The FDA label for zonisamide (sold under brand names such as Zonegran) classifies it as a prescription-only medication in the Anticonvulsant (Sulfonamide) class. Zonisamide is used to treat partial seizures in adults who have epilepsy. Official labeling lists 6 commonly reported side effects, including Feeling sleepy, Loss of appetite, Dizziness.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 14,210 voluntary reports. The database also lists 13 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS shows a generic unit cost of $0.10.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: August 1, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages